Breakthrough Could Lead to Better Stem Cell Production – R & D Magazine
R & D Magazine |
Breakthrough Could Lead to Better Stem Cell Production
R & D Magazine A research team has unlocked a potential alternative approach to manufacturing induced pluripotent stem cells (IPSCs). Scientists at The Scripps Research Institute (TSRI) found a way to harness antibodies that were able to help “reprogram” ordinary … |
EurekAlert (press release) |
Double agents: Vessels that help cancers spread can also boost immunotherapy
EurekAlert (press release) This process, lymphangiogenesis, also helps the tumor evade the patient’s own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of … Double agents: Vessels that help cancers spread can also boost immune therapiesMedical Xpress |
EurekAlert (press release) |
Double agents: Vessels that help cancers spread can also boost immunotherapy
EurekAlert (press release) This process, lymphangiogenesis, also helps the tumor evade the patient’s own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of … Lymph vessels that spread cancer can also help destroy tumoursBirmingham Mail |
|
Combination Immunotherapy Improves Kidney Cancer Survival
Newswise (press release) 12, 2017 – A combination immunotherapy treatment showed better overall survival in patients with previously untreated advanced or metastatic renal cell carcinoma than current therapy, according to results from a phase 3 clinical trial presented at the … |
Healio |
VIDEO: Gene alterations predict response to immunotherapy in urothelial carcinoma
Healio Alterations in DNA damage repair and response genes appear to improve response to immune checkpoint blockade among patients with urothelial carcinoma, according to findings presented at the ASCO Annual Meeting. These results “clearly” indicate that … |
Scientific American |
How Close Are We to a Lifelong Cure for Cancer?
Scientific American He developed methods to engineer a patient’s T cells into so-called chimeric antigen receptor T (CAR–T) cells, which recognize and kill a person’s unique cancer. This is called immunotherapy — training a person’s body to kill disease. One treatment … |